Symbol | Exchange | Currency |
|---|
Summit Therapeutics (SMMT)to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on...
Summit Therapeutics Inc (NASDAQ: SMMT) has selected a new preclinical candidate, SMT026738 (SMT-738), for development against multidrug-resistant infections, specifically...
Summit Therapeutics (SMMT) has selected a new preclinical candidate, SMT026738 (SMT-738), for development to treat multidrug resistant infections, specifically...
Summit Therapeutics plc (NASDAQ:SMMT) has been struggling lately, but the selling pressure may be coming to an end soon. That is because SMMT recently saw a Hammer Chart Pattern...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,442.50 | 2,461.90 | 2,436.70 | -4.1 | -0.17% | 957.49K | NASDAQ | |||
| 340.59 | 343.42 | 338.20 | +1.56 | +0.46% | 14.82M | NASDAQ | |||
| 1.31 | 1.37 | 1.305 | 0.0000 | 0.00% | 7.45M | NYSE | |||
| 58.30 | 61.10 | 56.80 | +0.03 | +0.05% | 116.20M | NYSE | |||
| 17.17 | 17.35 | 17.15 | +0.05 | +0.29% | 1.64M | NASDAQ | |||
| 214.86 | 216.33 | 213.13 | +3.54 | +1.68% | 13.78M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 19.14 | 19.50 | 18.86 | +0.10 | +0.53% | 784.87K | NYSE | |||
| 6.36 | 6.535 | 6.36 | 0.000 | 0.00% | 18.40M | NYSE | |||
| 24.12 | 24.69 | 23.38 | +0.33 | +1.39% | 598.12K | NASDAQ | |||
| 62.42 | 64.09 | 62.36 | -0.93 | -1.47% | 1.14M | NYSE | |||
| 24.70 | 25.56 | 24.66 | -0.02 | -0.08% | 4.36M | NYSE | |||
| 106.27 | 108.13 | 106.23 | -0.13 | -0.12% | 7.79M | NYSE | |||
| 15.74 | 16.29 | 15.72 | -0.06 | -0.38% | 3.02M | NYSE | |||
| 0.9039 | 0.00 | 0.00 | +0.0290 | +3.31% | 1.82M | NASDAQ |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
